SAN DIEGO, Jun 1, 2022 – Coastar Therapeutics Inc., an emerging biotech company focused on biological payload delivery technology for cancer immunotherapy and gene therapy, today announced that it is presenting at the BIO International Convention, June 13-16 2022. Eddie Y. Chung, CEO of Coastar Therapeutics, will be making a company presentation. Dr. Han L. Lim, Coastar’s Chief Science Officer, will be presenting at the Startup Stadium.  

Coastar Therapeutics has developed ENHEnS^TM, an innovative cell membrane coating technology platform that enables a wide range of biological payloads to avoid immune clearance and be successfully delivered to disease sites. The technology will lead to increased efficacy, reduced toxicity, lower cost and more applications in cancers and other diseases.

“Coastar’s ENHEnS technology will make a profound impact on many fields of medicine that utilize biologics as therapeutic agents, such as cancer immunotherapy, gene therapy, antibody, and vaccines. In addition to higher efficacy and wider applications, ENHEnS is also highly scalable. It will lower the cost of treatment and help millions of patients worldwide achieve better clinical outcome ” said Eddie Y. Chung, CEO of Coastar Therapeutics.

“On top of our oncolytic virus delivery pipelines, Coastar has made great progress to expand the ENHEnS cell membrane coating platform to the area of non viral gene therapy, which is highly sought after by the industry. We look forward to sharing our results with global colleagues at BIO”, said Han L. Lim, CSO of Coastar Therapeutics.

“We are excited about BIO 2022! The Coastar team looks forward to exploring collaborations with companies developing biological therapeutic products. Our ENHEnS platform is just what the market needs. ” said Chongyang Luo, head of business development of Coastar Therapeutics.

ABOUT COASTAR THERAPEUTICS

Coastar Therapeutics Inc., is a San Diego based company developing biological payload delivery technologies for cancer and gene therapies. The company’s proprietary ENHEnS^TM technology can coat cell membranes on biological payloads to help them evade recognition and clearance by the immune system and be successfully delivered to tumor or other disease sites. The company is developing therapeutic products for the cancer and gene therapy markets.